Celcuity (CELC) AI Stock Analysis

272 Followers

Top Page

Celcuity

(NASDAQ:CELC)

35Underperform

Celcuity's overall stock score is driven primarily by its challenging financial performance, characterized by consistent losses and high cash burn. The bearish technical indicators further weigh down the stock's attractiveness. Valuation offers some hope through potential future revenues from clinical programs, but the current lack of profitability and returns remains a concern.

Positive Factors

Financial Position

Celcuity ended the fourth quarter with $235 million, supporting operations through 2026.

Regulatory Approval

Gedatolisib has a breakthrough designation, leading to frequent interactions with the FDA.

Negative Factors

Financial Performance

The company reported no revenues and a net loss of $1.10 per diluted share for 4Q24, compared to consensus estimate of no revenues and a net loss of $0.71 per diluted share.

Market Sentiment

Short interest in the stock is relatively high at 15% of the float.

Celcuity (CELC) vs. S&P 500 (SPY)

Market Cap

$368.93M

Dividend YieldN/A

Average Volume (3M)351.42K

Price to Earnings (P/E)―

Beta (1Y)1.29

Revenue GrowthN/A

EPS Growth-4.14%

CountryUS

Employees87

SectorHealthcare

Sector Strength71

IndustryBiotechnology

Share Statistics

EPS (TTM)-2.81

Shares Outstanding37,839,394

10 Day Avg. Volume532,498

30 Day Avg. Volume351,415

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

Price to Cash Flow (P/CF)-4.70

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$30.43

Price Target Upside200.99% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Celcuity Business Overview & Revenue Model

Company DescriptionCelcuity Inc. is a biotechnology company focused on discovering new cancer sub-types and developing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. Operating primarily within the healthcare sector, Celcuity’s core product, CELsignia, is a platform that identifies the dynamic cellular activity in a patient's cancerous cells, helping to determine the most effective targeted therapy for their treatment.

How the Company Makes MoneyCelcuity generates revenue primarily through the commercialization of its CELsignia platform. The company's revenue model is based on partnerships with pharmaceutical companies and healthcare providers who utilize its diagnostic tests to optimize cancer treatment strategies. Celcuity collaborates with pharmaceutical firms to enhance the efficacy of their targeted therapies, potentially sharing in the economic benefits of improved treatment outcomes. Additionally, the company may receive payments for conducting clinical trials and providing diagnostic services to institutions focused on personalized cancer treatment.

Celcuity Financial Statement Overview

Summary

Celcuity's financial performance reflects typical challenges of early-stage biotech firms. The income statement shows significant profitability issues with deeply negative margins. The balance sheet is moderately strong with a healthy equity ratio, but cash flow analysis reveals sustained negative free cash flow, underscoring liquidity risks. Overall, financial stability is moderate but profitability is a critical concern.

Income Statement

Negative

Celcuity's income statement reflects significant challenges in profitability. The company reported a negative EBIT and EBITDA margin in the TTM period due to high operating expenses. Revenue growth cannot be calculated as past data is unavailable, but the TTM shows a small revenue figure indicating initial stages of commercialization. The net profit margin is deeply negative, highlighting a need for strategic adjustments to improve profitability.

Balance Sheet

Neutral

The balance sheet shows a moderate financial position with a debt-to-equity ratio of 0.65, suggesting manageable leverage. The equity ratio is 54.8%, indicating a healthy proportion of equity financing. However, the company's net income and ROE are negative, pointing to profitability challenges that could impact its ability to generate returns for shareholders.

Cash Flow

Negative

Cash flow analysis reveals negative free cash flow and operating cash flow, indicative of cash burn typical in early-stage biotech firms. The operating cash flow to net income ratio is positive, suggesting cash operations are slightly better than reported earnings. Nevertheless, sustained negative free cash flow poses risks to liquidity unless offset by continued financing.

TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Breakdown
Income Statement		Total Revenue
229.65K	0.00	0.00	0.00	0.00	0.00
	Gross Profit
141.03K	-142.77K	-210.92K	-303.24K	-385.59K	-339.00K
	EBIT
-96.57M	-66.23M	-39.39M	-28.36M	-9.56M	-7.81M
	EBITDA
-85.45M	-58.31M	-39.18M	-28.05M	-9.17M	-7.47M
	Net Income Common Stockholders
-93.97M	-63.78M	-41.35M	-30.56M	-9.09M	-7.02M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
5.07M	180.58M	168.59M	84.29M	11.64M	18.74M
	Total Assets
0.00	191.22M	175.70M	85.91M	12.96M	20.28M
	Total Debt
0.00	37.45M	35.24M	14.89M	262.49K	256.14K
	Net Debt
5.07M	6.78M	10.67M	-69.40M	-11.38M	-18.48M
	Total Liabilities
0.00	51.45M	41.93M	17.20M	1.25M	983.23K
	Stockholders Equity
5.02M	139.77M	133.77M	68.71M	11.70M	19.30M
Cash Flow		Free Cash Flow
-74.47M	-53.91M	-36.17M	-20.39M	-7.24M	-6.38M
	Operating Cash Flow
-74.23M	-53.81M	-36.01M	-20.31M	-7.15M	-6.00M
	Investing Cash Flow
-141.85M	-5.01M	-144.03M	-81.40K	-89.37K	8.53M
	Financing Cash Flow
202.92M	64.91M	120.33M	93.04M	137.97K	259.31K

Celcuity Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price10.11

Price Trends

50DMA

10.60

Negative

100DMA

11.49

Negative

200DMA

13.77

Negative

Market Momentum

MACD

-0.36

Negative

RSI

53.22

Neutral

STOCH

82.16

Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CELC, the sentiment is Neutral. The current price of 10.11 is above the 20-day moving average (MA) of 9.70, below the 50-day MA of 10.60, and below the 200-day MA of 13.77, indicating a neutral trend. The MACD of -0.36 indicates Negative momentum. The RSI at 53.22 is Neutral, neither overbought nor oversold. The STOCH value of 82.16 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CELC.

Celcuity Risk Analysis

Celcuity disclosed 47 risk factors in its most recent earnings report. Celcuity reported the most risks in the “Tech & Innovation” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Celcuity Peers Comparison

Overall Rating

UnderperformOutperform

Sector (50)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	50 Neutral	$5.51B	2.95	-43.70%	2.78%	16.94%	3.59%
ALT	49 Neutral	$356.57M	―	-59.86%	―	-95.31%	18.58%
ABVX	46 Neutral	$384.88M	―	-147.48%	―	―	-4.53%
AUTL	44 Neutral	$356.60M	―	-81.91%	―	496.00%	27.50%
RAPP	44 Neutral	$359.12M	―	-24.68%	―	―	―
ORIC	42 Neutral	$362.95M	―	-54.73%	―	―	7.15%
CELC	35 Underperform	$368.93M	―	-87.54%	―	―	-4.14%

* Healthcare Sector Average

Performance Comparison

CELC

Celcuity

10.11

-7.12

-41.32%

ALT

Altimmune

4.53

-2.99

-39.76%

AUTL

Autolus Therapeutics

1.40

-3.46

-71.19%

ORIC

Oric Pharmaceuticals

5.04

-4.41

-46.67%

ABVX

Abivax SA Sponsored ADR

6.06

-8.67

-58.86%

RAPP

Rapport Therapeutics, Inc.

9.60

-16.59

-63.34%

Celcuity Earnings Call Summary

Earnings Call Date: Mar 31, 2025 | % Change Since: 0.00% | Next Earnings Date: May 19, 2025

Earnings Call Sentiment Positive

The earnings call highlighted significant progress in clinical development programs and strong financial positioning, offset by increased net loss and expenses. The promising clinical data and potential for blockbuster revenue suggest a positive outlook.

Highlights

Progress in Clinical Development Programs

Celcuity completed enrollment of the PIK3CA wild-type cohort in the VIKTORIA-1 Phase III study and selection of approximately 200 sites for the VIKTORIA-2 Phase III study. The Phase Ib dose escalation study for prostate cancer is ongoing and on track for preliminary data by mid-2025.

Potential Blockbuster Revenue

Celcuity estimates that nearly 200,000 late-stage cancer patients globally could be eligible for treatment with gedatolisib, potentially generating blockbuster revenue if regulatory approvals are obtained.

Encouraging Overall Survival Data

Preliminary overall survival data from the Phase Ib study showed promising results, with median overall survival of 77 months for first-line patients and 34 months for second-line patients, compared favorably to published data.

Strong Financial Position

Celcuity ended fiscal 2024 with $235.1 million in cash, cash equivalents, and short-term investments, an increase of $54.5 million from the previous year.

Lowlights

Increased Net Loss

Celcuity reported a net loss of $36.7 million for Q4 2024, up from $18.8 million in Q4 2023. The full-year net loss for 2024 was $111.8 million, compared to $63.8 million in 2023.

Higher R&D and Administrative Expenses

Research and development expenses increased to $33.5 million in Q4 2024 from $18.1 million in Q4 2023. G&A expenses also rose to $3 million from $1.6 million in the same period.

Company Guidance

During the Celcuity Fourth Quarter and Full Year 2024 Financial Results Webcast Conference Call, several key metrics were discussed. The company reported a net loss of $36.7 million, or $0.85 per share, for the fourth quarter, compared to $18.8 million, or $0.65 per share, in the same period the previous year. For the full year 2024, the net loss totaled $111.8 million, or $2.83 per share, up from $63.8 million, or $2.69 per share, in 2023. The non-GAAP adjusted net loss for Q4 2024 was $32.3 million, or $0.75 per share, compared to $17.6 million, or $0.61 per share, in Q4 2023. For the full year, the non-GAAP adjusted net loss was $101.9 million, or $2.58 per share, versus $57.8 million, or $2.44 per share, in 2023. Research and development expenses rose to $33.5 million for the fourth quarter and $104.2 million for the year, driven by ongoing clinical trials. Celcuity ended the year with $235.1 million in cash and equivalents, up from $180.6 million at the end of 2023, following financing activities that raised $138.4 million.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.